share_log

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 50,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 50,000 Shares

奥普科健康公司(纳斯达克代码：OPK)首席执行官菲利普·马德等·弗罗斯特购买了50,000股
Defense World ·  2022/09/28 06:41

OPKO Health, Inc. (NASDAQ:OPK – Get Rating) CEO Phillip Md Et Al Frost acquired 50,000 shares of the stock in a transaction on Monday, September 26th. The stock was bought at an average price of $1.80 per share, with a total value of $90,000.00. Following the transaction, the chief executive officer now directly owns 197,756,694 shares in the company, valued at approximately $355,962,049.20. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

奥普科健康公司(纳斯达克代码：OPK-GET Rating)首席执行官菲利普·马德等·弗罗斯特在9月26日(星期一)的一笔交易中收购了50,000股该股。这只股票是以每股1.80美元的平均价格购买的，总价值为90,000.00美元。交易完成后，首席执行官现在直接拥有该公司197,756,694股，价值约355,962,049.20美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可以通过此超链接.

Phillip Md Et Al Frost also recently made the following trade(s):

菲利普·马德和阿尔·弗罗斯特最近还进行了以下交易：

Get
到达
OPKO Health
Opko Health
alerts:
警报：
  • On Friday, September 23rd, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.85 per share, with a total value of $92,500.00.
  • On Wednesday, September 21st, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.91 per share, with a total value of $95,500.00.
  • On Monday, September 19th, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.97 per share, with a total value of $98,500.00.
  • On Thursday, September 15th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $2.06 per share, with a total value of $412,000.00.
  • On Wednesday, August 17th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $2.54 per share, with a total value of $508,000.00.
  • On Friday, August 5th, Phillip Md Et Al Frost acquired 350,000 shares of OPKO Health stock. The shares were purchased at an average price of $2.29 per share, with a total value of $801,500.00.
  • 9月23日，星期五，Phillip Md et Al Frost购买了50,000股OPKO Health股票。这些股票是以每股1.85美元的平均价格收购的，总价值为92,500.00美元。
  • 9月21日，星期三，Phillip Md et Al Frost购买了50,000股OPKO Health股票。这些股票是以每股1.91美元的平均价格收购的，总价值为95,500.00美元。
  • 9月19日，星期一，Phillip Md et Al Frost购买了50,000股OPKO Health股票。这些股票是以每股1.97美元的平均价格收购的，总价值为98,500.00美元。
  • 9月15日星期四，Phillip Md et Al Frost购买了20万股OPKO Health股票。这些股票是以每股2.06美元的平均价格收购的，总价值为412,000.00美元。
  • 8月17日，星期三，Phillip Md et Al Frost购买了20万股OPKO Health股票。这些股票是以每股2.54美元的平均价格收购的，总价值为508,000.00美元。
  • 8月5日，星期五，Phillip Md et Al Frost收购了OPKO Health的350,000股股票。这些股票是以每股2.29美元的平均价格购买的，总价值为801,500.00美元。

OPKO Health Stock Performance

Opko Health股票表现

Shares of OPK opened at $1.86 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.91 and a current ratio of 2.30. OPKO Health, Inc. has a twelve month low of $1.78 and a twelve month high of $5.25. The firm's 50 day moving average price is $2.30 and its two-hundred day moving average price is $2.75. The firm has a market cap of $1.44 billion, a P/E ratio of -6.41 and a beta of 1.75.

周三，OPK的股价开盘报1.86美元。该公司的负债权益比率为0.12，速动比率为1.91，流动比率为2.30。Opko Health，Inc.的12个月低点为1.78美元，12个月高位为5.25美元。该公司的50日移动均线价格为2.30美元，200日移动均线价格为2.75美元。该公司的市值为14.4亿美元，市盈率为-6.41，贝塔系数为1.75。

OPKO Health (NASDAQ:OPK – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). OPKO Health had a negative net margin of 14.18% and a negative return on equity of 7.72%. The company had revenue of $309.90 million during the quarter, compared to the consensus estimate of $326.87 million. During the same period in the previous year, the firm posted ($0.03) EPS. The business's quarterly revenue was down 30.0% compared to the same quarter last year. On average, analysts forecast that OPKO Health, Inc. will post -0.38 EPS for the current fiscal year.
奥普科健康(纳斯达克代码：OPK-GET Rating)上一次公布季度收益是在8月4日(星期四)。这家生物技术公司公布的季度每股收益为0.04美元，低于分析师普遍预期的0.02美元和0.02美元。Opko Health的净利润率为负14.18%，股本回报率为负7.72%。该公司本季度营收为3.099亿美元，而市场普遍预期为3.2687亿美元。去年同期，该公司公布的每股收益为0.03美元。与去年同期相比，该业务的季度收入下降了30.0%。分析师平均预测，OPKO Health，Inc.本财年每股收益将为0.38美元。

Analyst Ratings Changes

分析师评级发生变化

Separately, Piper Sandler decreased their price objective on shares of OPKO Health from $5.00 to $4.00 and set an "overweight" rating for the company in a report on Friday, August 5th.

另外，派珀·桑德勒将OPKO Health的股票目标价从5.00美元下调至4.00美元，并在8月5日星期五的一份报告中为该公司设定了“增持”评级。

Institutional Trading of OPKO Health

OPKO Health的制度性交易

Institutional investors have recently made changes to their positions in the business. Cornerstone Advisory LLC bought a new stake in shares of OPKO Health in the fourth quarter worth $29,000. Humankind Investments LLC bought a new stake in shares of OPKO Health in the first quarter worth $37,000. Guggenheim Capital LLC bought a new stake in shares of OPKO Health in the first quarter worth $38,000. Point72 Hong Kong Ltd bought a new stake in shares of OPKO Health in the first quarter worth $39,000. Finally, Aigen Investment Management LP bought a new stake in shares of OPKO Health in the second quarter worth $29,000. Institutional investors own 27.83% of the company's stock.

机构投资者最近对他们在该业务中的头寸进行了调整。基石咨询有限责任公司在第四季度购买了OPKO Health价值2.9万美元的新股。人类投资有限责任公司在第一季度购买了OPKO Health价值3.7万美元的新股份。古根海姆资本有限责任公司在第一季度购买了OPKO Health价值3.8万美元的新股份。Point72 Hong Kong Ltd在第一季度购买了OPKO Health价值3.9万美元的新股。最后，Aigen Investment Management LP在第二季度购买了OPKO Health价值2.9万美元的新股。机构投资者持有该公司27.83%的股份。

About OPKO Health

关于OPKO健康

(Get Rating)

(获取评级)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Opko Health，Inc.是一家医疗保健公司，在美国、爱尔兰、智利、西班牙、以色列、墨西哥和国际上从事诊断和制药业务。该公司的诊断部门经营着BioReference实验室，该实验室为疾病的检测、诊断、评估、监测和治疗提供实验室测试服务，包括深奥测试、分子诊断、解剖病理学、遗传学、妇女健康以及为医生办公室、诊所、医院、雇主和政府单位提供的矫正保健；以及在护理地点提供血液测试结果的新型诊断仪器系统，以及4KScore前列腺癌测试服务。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on OPKO Health (OPK)
  • Defensive Stocks For A Volatile Market
  • Will UPS Be Next to Deliver a Warning?
  • SunPower Is Ready To Power Up Triple-Digit Earnings Gains
  • Is This the Darkest Before the Dawn for Gap Stock?
  • Build A Better Tech Portfolio With Jabil Inc.
  • 免费获取StockNews.com关于OPKO健康的研究报告(OPK)
  • 防御性股票应对动荡的市场
  • UPS会成为下一个发出警告的公司吗？
  • SunPower准备推动三位数的收益增长
  • 这是Gap Stock黎明前最黑暗的一次吗？
  • 与捷普公司一起打造更好的技术产品组合。

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

接受OPKO健康日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对OPKO Health和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发